Skip to main content
. 2020 Feb 17;12(2):222. doi: 10.3390/v12020222

Figure 3.

Figure 3

Kinetics of serum biomarkers of the immune response in a Yellow fever patient compared to the healthy control group. (A) Chemokine levels (CXCL8, CCL11, CCL3, CCL4, CCL2, CCL-5, and CXCL10); (B) Pro-inflammatory cytokine levels (IL1-β, IL-6, TNF-α, IL-12, IFN-ɣ, IL-15 and IL-17); (C) Regulatory cytokine levels (IL-1Ra, IL-4, IL-5, IL-9, IL-10 and IL-13); (D) Growth factors levels (FGF-basic, PDGF, VEGF, G-CSF, GM-CSF, IL-2 and IL-7) were measured at the 36th, 78th, 197th and 306th day post-symptom onset by high-performance microbeads 27-plex assay, as described in File S1. Green arrows represent increased (up) or decreased (down) levels of serum biomarkers in comparison to the 95% confidence interval (CI) of the mean values found in the reference control group (n = 16) underscored by gray boxes.